The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Timothy Ritter, MD: Real-World Data Supporting Fecal Microbiota for Recurrent C Diff
Ritter reviews findings from 2 real-world studies supporting the safety and efficacy of live-jslm (Rebyota) for recurrent C Diff infection.
AIMS65 Could Predict Treated Gastrointestinal Bleed Death, Rebleed Risks
New late-breaking ACG 2024 data supports AIMS65 as a risk factor tool for patients undergoing anticoagulant reversal.
Zegocractin Significantly Improves Acute Pancreatitis Symptoms in Phase 2 CARPO
The CRAC channel inhibitor zegocractin significantly improved acute pancreatitis patients' time to eating food and risk of respiratory failure in new data.
Infliximab Improves Ulcerative Colitis, Crohn's Disease Regardless of Immunosuppressants
Post hoc analyses from the LIBERTY trials support infliximab as either a monotherapy or combination therapy for ulcerative colitis or Crohn's disease.
Collaboration, Intralesional Therapies for Skin Cancer, with Laura K. Ferris, MD, PhD, and Neal Bhatia, MD
This interview features a discussion with Bhatia and Ferris regarding the necessity of collaboration between dermatologists and oncologists for skin cancer.
What Are Some Other Methods To Manage Skin Cancer Outside of Biopsies?
In this interview, Neal Bhatia, MD, and Laura Korb Ferris, MD, PhD, spoke on their Fall Clinical Conference talk titled ‘Beyond the Biopsy: Other Methods To Help Us Manage Skin Cancer.’
Brian Lacy, MD, PhD: Rethinking Motility Testing with a Noninvasive Wireless Patch System
Lacy explains limitations to current motility measurements and reviews findings from his study exploring the potential of a wireless motility patch system.
Kidney Compass: Semaglutide for Nondiabetic Kidney Disease, with Hiddo Heerspink, PhD, PharmD, at Kidney Week 2024
Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
This interview with Bunick highlighted the Level Up phase 3b/4 trial findings regarding upadacitinib treatment of patients with atopic dermatitis.
Kidney Compass: Atacicept for IgAN with Jonathan Barratt, MD, PhD, at Kidney Week 2024
Neuen, Wadhwani, and Barratt discuss atacicept promise in IgA nephropathy based on phase 2b ORIGIN OLE results, at-home use, and the future of kidney disease care.
ORIGIN OLE Data Solidify Atacicept Disease-Modifying Potential for IgA Nephropathy
New ORIGIN trial data show atacicept may slow kidney decline in IgA nephropathy to rates seen with healthy aging, with notable reductions in Gd-IgA1 and UPCR.
Julie Refardt, MD, PhD: Current Hyponatremia Clinical Interventions Sufficient
Refardt discussed findings from the largest hyponatremia trial ever conducted, including 2174 participants across 9 European centers.
Patient-Reported Outcomes for Roflumilast Foam Highlighted for Seborrheic Dermatitis
These findings from the phase 3 STRATUM trial suggest significant DLQI score improvements as early as the second week of treatment with roflumilast foam.
Dapagliflozin Lowers Risk of Decline in Late-Stage Kidney Disease
The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.
Richard Pratley, MD: FLOW Mortality Data and Allocation Strategies for Semaglutide
Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.
Christopher Bunick, MD, PhD: Facts About Systemic Therapies’ Safety, Mechanism of Action
In this interview, Bunick spoke about the contents of his Fall Clinical Dermatology presentation specifically regarding mechanisms of action and safety of systemic therapies.
Semaglutide Shows Benefit in CKD and Type 2 Diabetes Across Kidney Disease Severities
Participants receiving semaglutide had an overall hazard ratio of 0.76 in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo.
Carla Nester, MD: Pegcetacoplan in C3 Glomerulopathy and Primary IC-MPGN
Carla Nester, MD, provides perspective on the results of the VALIANT trial and how it informs the role of pegcetacoplan in C3G and IC-MPGN .
VALIANT: Pegcetacoplan Offers Benefit for UPCR, eGFR, C3 Staining in C3G, IC-MPGN
VALIANT trial data support pegcetacoplan as the first effective therapy for proteinuria, C3c staining, and eGFR stability in C3G and IC-MPGN patients.
Despite Guidelines, Systemic Corticosteroids Remain Widely Prescribed for Atopic Dermatitis
In these data presented at the Fall Clinical Dermatology conference, population-based data on utilization and duration of systemic corticosteroid exposure was highlighted.
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
In this interview, Kwatra highlighted several key takeaways from his talks on prurigo nodularis, atopic dermatitis, and itch at the Fall Clinical Dermatology Conference.
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Herrington shared the carryover effects observed in the post-trial follow-up of the phase 3 EMPA-KIDNEY trial.
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Yee discussed how the data show a benefit in this hard-to-treat population, which was not seen in the heterogeneous FSGS group.
KAT-AKI: Tailored EHR Alerts Fail to Improve AKI Management in Hospitalized Patients
Yale's KAT-AKI trial found personalized EHR alerts for AKI management improved clinician actions but didn't reduce progression, dialysis, or mortality rates in patients.
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
In this interview segment, Del Rosso highlighted his Fall Clinical presentation takeaways covered in the talk ‘What’s New in the Medicine Chest - Part 2.’
Ladan Zand, MD: Obinutuzumab a Promising Option for Refractory, Primary FSGS
Zand discussed interim 12-month findings from an open-label, phase 2 trial currently ongoing for patients with refractory primary focal segmental glomerulosclerosis.
Semaglutide Shows Promise, Reduces UACR in Nondiabetic Kidney Disease
New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.
New Phase 3b Findings Suggest Lebrikizumab Improved Skin, Itch for Atopic Dermatitis
These data from the ADapt study, presented at Fall Clinical, suggest improvements among patients with eczema given lebrikizumab-lbkz who had been previously treated with dupilumab.
Empagliflozin Benefits on Kidney Disease Progression, Death Continue for 1 Year Post-Discontinuation
After discontinuing therapy, treated participants still had an overall 13% reduction in the risk of kidney disease progression or cardiovascular death.
Finerenone Use Reduces UACR, New-Onset Macroalbuminuria in Heart Failure Patients
New FINEARTS-HF data shows that finerenone reduces albuminuria in patients with HFmrEF or HFpEF, but without significant eGFR changes.